DSG3 and myasthenia gravis: We recently introduced a novel genetically engineered cellular immunotherapy named chimeric autoantibody receptor T cells (CAART) for the treatment of autoantibody-mediated diseases, including desmoglein 3 (DSG3)–seropositive mucosal pemphigus vulgaris and MuSK-MG (10–12).